Radiopharmaceuticals

PET Products Portfolio

Isotopia's nuclear pharmacy produces and distributes PET radiopharmaceuticals to nuclear medicine centers throughout Israel. Our portfolio includes F-18 and Ga-68 labeled tracers, including FDG, F18-DOPA, F18-PSMA, Ga68-PSMA, Ga68-DOTATATE, supporting a broad range of clinical applications in oncology and molecular imaging—from routine metabolic imaging to prostate cancer detection and neuroendocrine tumor localization.

Every batch is manufactured under cGPP conditions, calibrated to customer specifications, and delivered with comprehensive quality documentation, ready for same-day clinical use.

PET Products Intro
Our PET Products

18F-FDG

Product Overview
18F-FDG is a fluorine-18 labelled radiopharmaceutical prepared under stringent cGPP conditions in Isotopia's Nuclear Pharmacy. As the gold-standard PET tracer for imaging glucose metabolism, it supports accurate diagnosis, disease staging, therapy response assessment and patient follow-up across a broad range of oncological, neurological and inflammatory diseases. Manufactured to deliver consistently high radiochemical quality, 18F-FDG provides reliable performance for routine clinical PET/CT imaging.

Clinical Applications

  • Detection, staging and restaging of malignant disease
  • Assessment of response to oncological therapy
  • Detection of recurrent malignancy
  • Evaluation of epilepsy
  • Assessment of dementia
  • Inflammatory and infectious diseases

18F-PSMA-1007

Product Overview
18F-PSMA-1007 provides excellent lesion detectability through high-quality PET imaging with reduced urinary bladder activity, supporting accurate evaluation of prostate cancer. Careful preparation under cGPP conditions provides reliable image quality and reproducible performance for disease staging, recurrence detection and treatment planning.

Clinical Applications

  • Primary staging
  • Biochemical recurrence
  • Treatment planning

18F-FDOPA

Product Overview
18F-FDOPA is a specialized PET radiopharmaceutical prepared under cGPP conditions for imaging dopaminergic pathways and selected neuroendocrine tumours. The product offers consistent radiochemical quality and dependable performance for medical centres performing advanced neurological and oncological PET imaging.

Clinical Applications

  • Parkinsonian syndromes
  • Neuroendocrine tumours
  • Congenital hyperinsulinism

18F-AlF-NOTA-Octreotide

Product Overview
18F-AlF-NOTA-Octreotide combines the logistical advantages of fluorine-18 with somatostatin receptor targeting, providing high-quality PET imaging for neuroendocrine tumour evaluation.

Clinical Applications

  • Neuroendocrine tumours

68Ga-DOTATATE

Product Overview
68Ga-DOTATATE is prepared for PET imaging of somatostatin receptor-positive neuroendocrine tumours. It is a well-established imaging radiopharmaceutical for diagnosis, staging and treatment selection of neuroendocrine tumours and combines reliable radiochemical performance with consistent preparation to support confident clinical decision-making.

Clinical Applications

  • Diagnosis of NETs
  • Staging
  • Restaging
  • PRRT patient selection

68Ga-PSMA-11

Product Overview
68Ga-PSMA-11 provides sensitive PET imaging of PSMA-positive prostate cancer lesions. Prepared under controlled cGPP conditions, it supports accurate localization of disease and informed patient management.

Clinical Applications

  • Initial staging
  • Recurrence
  • Metastatic disease assessment

Why Choose Isotopia?

Prepared under stringent cGPP conditions
Consistent radiochemical quality
Reliable, timely supply for clinical use
Professional technical support from experienced Nuclear Pharmacists